These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38783078)

  • 1. Genome-wide identification and analysis of epithelial-mesenchymal transition-related RNA-binding proteins and alternative splicing in a human breast cancer cell line.
    Mi Y; Dong M; Zuo X; Cao Q; Gu X; Mi H; Xiao F
    Sci Rep; 2024 May; 14(1):11753. PubMed ID: 38783078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combinatorially regulated RNA splicing signature predicts breast cancer EMT states and patient survival.
    Qiu Y; Lyu J; Dunlap M; Harvey SE; Cheng C
    RNA; 2020 Sep; 26(9):1257-1267. PubMed ID: 32467311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of RNA-binding protein and alternative splicing event associations during epithelial-mesenchymal transition based on inductive matrix completion.
    Qiu Y; Ching WK; Zou Q
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33517359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
    Vadlamudi Y; Dey DK; Kang SC
    Curr Cancer Drug Targets; 2020; 20(9):654-665. PubMed ID: 32564755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT.
    Harvey SE; Xu Y; Lin X; Gao XD; Qiu Y; Ahn J; Xiao X; Cheng C
    RNA; 2018 Oct; 24(10):1326-1338. PubMed ID: 30042172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.
    Fici P; Gallerani G; Morel AP; Mercatali L; Ibrahim T; Scarpi E; Amadori D; Puisieux A; Rigaud M; Fabbri F
    Oncotarget; 2017 Jan; 8(2):2423-2436. PubMed ID: 27911856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
    Block CJ; Mitchell AV; Wu L; Glassbrook J; Craig D; Chen W; Dyson G; DeGracia D; Polin L; Ratnam M; Gibson H; Wu G
    Oncogene; 2021 Nov; 40(46):6430-6442. PubMed ID: 34608266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCB: A pseudotemporal causality-based Bayesian approach to identify EMT-associated regulatory relationships of AS events and RBPs during breast cancer progression.
    Sun L; Qiu Y; Ching WK; Zhao P; Zou Q
    PLoS Comput Biol; 2023 Mar; 19(3):e1010939. PubMed ID: 36930678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.
    Shapiro IM; Cheng AW; Flytzanis NC; Balsamo M; Condeelis JS; Oktay MH; Burge CB; Gertler FB
    PLoS Genet; 2011 Aug; 7(8):e1002218. PubMed ID: 21876675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix factorization-based data fusion for the prediction of RNA-binding proteins and alternative splicing event associations during epithelial-mesenchymal transition.
    Qiu Y; Ching WK; Zou Q
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34410342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing.
    Hu X; Harvey SE; Zheng R; Lyu J; Grzeskowiak CL; Powell E; Piwnica-Worms H; Scott KL; Cheng C
    Nat Commun; 2020 Jan; 11(1):486. PubMed ID: 31980632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.
    Xue JQ; Xia TS; Liang XQ; Zhou W; Cheng L; Shi L; Wang Y; Ding Q
    BMC Cancer; 2014 May; 14():322. PubMed ID: 24884756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer.
    Elhasnaoui J; Ferrero G; Miano V; Franchitti L; Tarulli I; Coscujuela Tarrero L; Cutrupi S; De Bortoli M
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer.
    Li J; Choi PS; Chaffer CL; Labella K; Hwang JH; Giacomelli AO; Kim JW; Ilic N; Doench JG; Ly SH; Dai C; Hagel K; Hong AL; Gjoerup O; Goel S; Ge JY; Root DE; Zhao JJ; Brooks AN; Weinberg RA; Hahn WC
    Elife; 2018 Jul; 7():. PubMed ID: 30059005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition.
    Aparicio LA; Abella V; Valladares M; Figueroa A
    Cell Mol Life Sci; 2013 Dec; 70(23):4463-77. PubMed ID: 23715860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing factor
    Gökmen-Polar Y; Neelamraju Y; Goswami CP; Gu Y; Gu X; Nallamothu G; Vieth E; Janga SC; Ryan M; Badve SS
    EMBO Rep; 2019 Feb; 20(2):. PubMed ID: 30665944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome-wide analysis reveals the coregulation of RNA-binding proteins and alternative splicing genes in the development of atherosclerosis.
    Wang R; Xu J; Tang Y; Wang Y; Zhao J; Ding L; Peng Y; Zhang Z
    Sci Rep; 2023 Jan; 13(1):1764. PubMed ID: 36720950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP.
    Horiguchi K; Sakamoto K; Koinuma D; Semba K; Inoue A; Inoue S; Fujii H; Yamaguchi A; Miyazawa K; Miyazono K; Saitoh M
    Oncogene; 2012 Jun; 31(26):3190-201. PubMed ID: 22037216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Alternative Splicing during Epithelial-Mesenchymal Transition.
    Lyu J; Cheng C
    Cells Tissues Organs; 2022; 211(2):238-251. PubMed ID: 34348273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pro-metastasis effect of circANKS1B in breast cancer.
    Zeng K; He B; Yang BB; Xu T; Chen X; Xu M; Liu X; Sun H; Pan Y; Wang S
    Mol Cancer; 2018 Nov; 17(1):160. PubMed ID: 30454010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.